US-based biopharmaceutical services company Quintiles has formed a strategic alliance with the UK’s London Genetics under which the new partners will offer the biopharmaceutical industry innovative pharmacogenetics solutions to advance the cause of personalised medicine.
The financial terms of the non-exclusive alliance were not disclosed. Quintiles and London Genetics will work together to help biopharmaceutical companies take advantage of pharmacogenetics solutions including novel biomarker and assay development services.
A not-for-profit company set up in 2007 with funding from the London Development Agency, London Genetics works with centres of excellence for genetics research based in the UK capital to provide pharmaceutical companies with access to know-how and patient resources.
Its seven founding partners are leading academic and medical institutions with clinical and genetic expertise. The company also gives strategic advice on applying pharmacogenetics for successful drug development. It helps companies to partner with relevant academics and clinicians, apply genetic knowledge to take some of the risk out of clinical trials, design and manage projects and to access patient cohorts.
For its part, Quintiles develops proprietary and novel biomarker tests to analyse genes and proteins that affect cell growth and mutation. It then performs these assays at laboratories in the US, Scotland and China.
The company says it has the largest central laboratory network in the world, with wholly owned facilities in the US, Europe, South Africa, India, China, Singapore and Japan, as well as a network of affiliate laboratories in Argentina and Brazil.
Biopharmaceutical companies are “under relentless pressure to replenish their product pipelines and deliver safer, more effective medicines to patients in need,” noted Thomas Wollman, senior vice president, Quintiles Global Central Laboratories.
“Through our alliance with London Genetics, we have world-class expertise to help early adopters of personalised medicine use genomic technologies to improve drug discovery and development, and a networked infrastructure to support those efforts virtually anywhere in the world,” Wollman added.
“Our expertise in pharmacogenetic strategy development combined with Quintiles’ expertise and infrastructure in biomarker development gives biopharma companies a powerful ally in harnessing the value of genomic data for drug development,” commented Dominique Kleyn, chief executive officer of London Genetics.